SOURCE: Fresenius Medical Care

Fresenius Medical Care

August 21, 2015 00:51 ET

Fresenius Medical Care ACHSi Organisational Wide Survey for Accreditation Results in Certification of All NephroCare Clinics

HONG KONG, CHINA--(Marketwired - Aug 21, 2015) - Fresenius Medical Care, THE RENAL COMPANY, celebrated the ACHSi accreditation of NephroCare Wan Chai and NephroCare Tuen Mun. This achievement follows the success of St. Paul NephroCare which gained its accreditation last May 2014.

Speaking at the ACHSi Accreditation Ceremony, Dr. Kelvin Ho, Medical Director of NephroCare Wan Chai commented that: "NephroCare Wan Chai Haemodialysis Centre has aimed at providing the highest standards of medical care and service to our patients ever since the centre opened in 2013. Today's ACHSi accreditation with a high standard of achievement is a significant milestone and is a recognition of the quality-driven approach to care in our centre. It is not just a reassurance of the continuous hard work by our team, but more importantly, it gives our patients confidence in receiving the highest standard of care and services to treat their illnesses in our centre.

Dr. Ho Yiu Wing, Medical Director at NephroCare Tuen Mun added that: "With the accreditation process, our team was more alert in documentation and in the establishment of standard procedures. All of our patients are assured to receive adequate dialysis and tailored care. During the accreditation exercise, our nursing team exemplified team spirit, and to this day the team spirit persists!"

Mr. Thorsten Bruce, General Manager of Fresenius Medical Care Hong Kong said, "We have always strived to put our patients first and provide excellent care. The ACHSi certification was a significant undertaking for NephroCare Wan Chai and NephroCare Tuen Mun and we were delighted to be honoured with four Excellent Extensive Achievement Awards." Mr. Bruce added that the Awards were given in the areas of Outcomes & Evaluation of Patient Care; High Quality Safe Healthcare; Information Management Systems; and Care and Services in the most appropriate & effective way.

NephroCare is the renal service arm of Fresenius Medical Care which provides life-saving dialysis care to 286,000 patients in its global network of 3,360 renal services clinics.

Image
Accreditation Award Ceremony
(Left to right) Candy Chan, Head Nurse at NephroCare Wan Chai, Thorsten Bruce, General Manager of Fresenius Medical Care Hong Kong, Dr. Kelvin Ho, Medical Director at NephroCare Wan Chai, Dianna Kenrick, Senior Director Clinical Quality of Fresenius Medical Care, AP Dr. Desmond Yen, Executive Director, International Business, ACHS
http://release.media-outreach.com/i/Download/3541

Accreditation Award Ceremony
(Left to right) Thorsten Bruce, General Manager of Fresenius Medical Care Hong Kong, Alexandra Lai, Head Nurse at NephroCare Tuen Mun, Dr. Ho Yiu Wing, Medical Director at NephroCare Tuen Mun, Dianna Kenrick, Senior Director Clinical Quality of Fresenius Medical Care, AP Dr. Desmond Yen, Executive Director, International Business, ACHS
http://release.media-outreach.com/i/Download/3542

Company logo
http://release.media-outreach.com/i/Download/1869

ABOUT FRESENIUS MEDICAL CARE:
Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2.7 million individuals worldwide. Through its network of 3,361 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatments for 286,312 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.

For more information visit the Company's website at www.freseniusmedicalcare.com.

Disclaimer
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Contact Information

  • Contact
    Ms. Eonjung Lim
    Marketing Communications
    Fresenius Medical Care
    Email: Email Contact